Online inquiry

IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5343MR)

This product GTTS-WQ5343MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5343MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12855MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ5206MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ9851MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ4600MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ10955MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ10112MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ9579MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ14692MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW